. 2018 Apr 30;12:275. doi: 10.3389/fnins.2018.00275

Table 1.

Neuroimaging biomarkers in Alzheimer's disease.

Neuroimaging biomarker	Biomarker readout associated with AD
MRI^*	Atrophy
fMRI	Disrupted neural network
¹¹C-PIB PET^*	Increased amyloid plaque binding to PIB
¹⁸F-Aβ-binding compound-PET^**	Higher amount of amyloid in brain
¹⁸FDG-PET^*	Low brain metabolism measured by decreased glucose uptake

Aβ, amyloid beta; AD, Alzheimer's disease; FDG, fluoro-2-deoxy-D-glucose; fMRI, functional MRI; MRI, magnetic resonance imaging; PET, positron emission tomography; PIB, Pittsburgh compound B.

Included in the NIA-2011 and IWG−2014 criteria to support diagnosis of AD for research purposes.

^**

Approved by FDA and EMA.